Ann: FDA Clears Development Path for BTX 1204, page-22

I've got plenty parked here at BOT , certainly in my Top 5 investments. 

The information released in regard to continually benefiting the Trial Patient should have been welcomed, for us that follow this stock closely/daily then "WE' are in the know that our Premium Product although only monitored under the Trial ( Trial Period ) has continued to benefit Patients beyond the trial period TERM.

The Next major announcement will be with Graphics demonstrating to those with the naked eye and you wont need a PHD to see the visual overwhelming benefits.

You will always get leakage of info from Trial Patients and Family members, it's the nature of the beast,, if your Son who has had (all previous medical treatment fail) and his face is cleaning up like a Russian Doll , you are going to tell others that the product your son is part of the trial works... people ask the trial patient directly,,Mate your face is looking great,,what have you been doing?? some will decide to pursue a financial investment based on the results in front of them...

WHY is BOT for me,,, on the complexity scale of medicine Derma application is close to the bottom, Results are visually recognised, Billions of People require this product.

There have been two players for 18 years licensing out Benzine Peroxide and Peroxide derivatives to encompass roughly 2000 different branded Products ,, BOT Trial Derma Application (cream) has OUT Performed All Products on the Market,, with no Adverse Side Effects..

DSMB will find it easy to approve, results will speak volumes, FDA will welcome a non invasive remedy .

BOT have Disruptive Technology, it's a Market Changer,,, do we have the Management to Commercialise the Technology, YES... 

CR's are part of the early life of a Biotech,, Management should now be focused on a commercialisation Agreement, this will inject a large solid lump, similar to ACW ( they received $15m at premium for Phase III when they released interim Phase II results)

BOT are cashed up, plenty in the bank enabling a clear cash runway for the completion of multi trials... 

We still have the Giant Rinse to go of the last CR @ 11c our Insto has not been able to rinse any back to market at a premium,, if anyone was going to be in the ear of Management it would be them.. Management would have received many emails from Shareholders questioning the timing of yet another CR... Hopefully this has informed Management that Shareholders require a commercial deal now moving forward... 

Discussions turn very quickly to Negotiations with Positive Results in Hand.. 

My Pick is we will begin the climb again next week ,, finishing next Friday at 12 to 13c... NZT